Zentalis Pharmaceuticals Presents Updated Azenosertib Clinical Data at the Society of Gynecologic Oncology 2025 Annual Meeting on Women’s Cancer
SAN DIEGO, March 15, 2025 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company developing a potentially first-in-class and best-in-class WEE1 inhibitor for patients with ovarian cancer...
